Treatment With Hepcludex (bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 24, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from the Phase 2b and Phase 3 clinical trials evaluating the first-in-class entry inhibitor...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials